An Appraisal of Bacteriophage Isolation Techniques from Environment

Overview

Journal Microb Ecol

Specialties Environmental Health
Microbiology

Date 2021 Jun 17

PMID 34136953

Citations 5

Authors

Aparna Nair

Gaurav S Ghugare

Krishna Khairnar

Affiliations

Soon will be listed here.

Abstract

Researchers have recently renewed interest in bacteriophages. Being valuable models for the study of eukaryotic viruses, and more importantly, natural killers of bacteria, bacteriophages are being tapped for their potential role in multiple applications. Bacteriophages are also being increasingly sought for bacteriophage therapy due to rising antimicrobial resistance among pathogens. Reports show that there is an increasing trend in therapeutic application of natural bacteriophages, genetically engineered bacteriophages, and bacteriophage-encoded products as antimicrobial agents. In view of these applications, the isolation and characterization of bacteriophages from the environment has caught attention. In this review, various methods for isolation of bacteriophages from environmental sources like water, soil, and air are comprehensively described. The review also draws attention towards a handful on-field bacteriophage isolation techniques and the need for their further rapid development.

Citing Articles

phage ΦPNJ-9 adheres to mucus via a variant Hoc protein.

Fu K, Cui J, Li Y, Zhang Y, Wang Y, Wu J J Virol. 2024; 99(2):e0178924.

PMID: 39723818 PMC: 11853027. DOI: 10.1128/jvi.01789-24.

Phage therapy to treat cystic fibrosis complex lung infections: perspectives and challenges.

Canning J, Laucirica D, Ling K, Nicol M, Stick S, Kicic A Front Microbiol. 2024; 15:1476041.

PMID: 39493847 PMC: 11527634. DOI: 10.3389/fmicb.2024.1476041.

Characterization of a Diverse Collection of Salmonella Phages Isolated from Tennessee Wastewater.

Bryan D, Hudson L, Wang J, Denes T Phage (New Rochelle). 2023; 4(2):90-98.

PMID: 37350991 PMC: 10282790. DOI: 10.1089/phage.2023.0004.

Current Clinical Landscape and Global Potential of Bacteriophage Therapy.

Hitchcock N, Nunes D, Shiach J, Hodel K, Barbosa J, Alencar Pereira Rodrigues L Viruses. 2023; 15(4).

PMID: 37113000 PMC: 10146840. DOI: 10.3390/v15041020.

Bacteriophage therapy in aquaculture: current status and future challenges.

Liu R, Han G, Li Z, Cun S, Hao B, Zhang J Folia Microbiol (Praha). 2022; 67(4):573-590.

PMID: 35305247 DOI: 10.1007/s12223-022-00965-6.

References

Tokarz-Deptula B, Niedzwiedzka-Rystwej P, Czuprynska P, Deptula W . Protozoal giant viruses: agents potentially infectious to humans and animals. Virus Genes. 2019; 55(5):574-591. PMC: 6746690. DOI: 10.1007/s11262-019-01684-w. View

Lin D, Koskella B, Lin H . Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017; 8(3):162-173. PMC: 5547374. DOI: 10.4292/wjgpt.v8.i3.162. View

Karimi M, Mirshekari H, Moosavi Basri S, Bahrami S, Moghoofei M, Hamblin M . Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos. Adv Drug Deliv Rev. 2016; 106(Pt A):45-62. PMC: 5026880. DOI: 10.1016/j.addr.2016.03.003. View

Adriaenssens E, Van Vaerenbergh J, Vandenheuvel D, Dunon V, Ceyssens P, De Proft M . T4-related bacteriophage LIMEstone isolates for the control of soft rot on potato caused by 'Dickeya solani'. PLoS One. 2012; 7(3):e33227. PMC: 3296691. DOI: 10.1371/journal.pone.0033227. View

Fujiwara A, Fujisawa M, Hamasaki R, Kawasaki T, Fujie M, Yamada T . Biocontrol of Ralstonia solanacearum by treatment with lytic bacteriophages. Appl Environ Microbiol. 2011; 77(12):4155-62. PMC: 3131639. DOI: 10.1128/AEM.02847-10. View

Benhar I . Biotechnological applications of phage and cell display. Biotechnol Adv. 2003; 19(1):1-33. DOI: 10.1016/s0734-9750(00)00054-9. View

Ronca R, Benzoni P, De Luca A, Crescini E, DellEra P . Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics. Int J Mol Sci. 2012; 13(4):5254-5277. PMC: 3344278. DOI: 10.3390/ijms13045254. View

Ahmed A, Rushworth J, Hirst N, Millner P . Biosensors for whole-cell bacterial detection. Clin Microbiol Rev. 2014; 27(3):631-46. PMC: 4135896. DOI: 10.1128/CMR.00120-13. View

Majewska J, Beta W, Lecion D, Hodyra-Stefaniak K, Klopot A, Kazmierczak Z . Oral Application of T4 Phage Induces Weak Antibody Production in the Gut and in the Blood. Viruses. 2015; 7(8):4783-99. PMC: 4576206. DOI: 10.3390/v7082845. View

10.

Kazmierczak Z, Gorski A, Dabrowska K . Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. Viruses. 2014; 6(7):2551-70. PMC: 4113783. DOI: 10.3390/v6072551. View

11.

Gorski A, Miedzybrodzki R, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Rogoz P . Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases. Front Microbiol. 2016; 7:1515. PMC: 5035766. DOI: 10.3389/fmicb.2016.01515. View

12.

Shlezinger M, Khalifa L, Houri-Haddad Y, Coppenhagen-Glazer S, Resch G, Que Y . Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens. Curr Top Med Chem. 2016; 17(10):1199-1211. DOI: 10.2174/1568026616666160930145649. View

13.

OFlaherty S, Ross R, Coffey A . Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev. 2009; 33(4):801-19. DOI: 10.1111/j.1574-6976.2009.00176.x. View

14.

Wittebole X, De Roock S, Opal S . A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2013; 5(1):226-35. PMC: 3916379. DOI: 10.4161/viru.25991. View

15.

Soothill J . Treatment of experimental infections of mice with bacteriophages. J Med Microbiol. 1992; 37(4):258-61. DOI: 10.1099/00222615-37-4-258. View

16.

Merril C, Biswas B, Carlton R, Jensen N, Creed G, Zullo S . Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A. 1996; 93(8):3188-92. PMC: 39580. DOI: 10.1073/pnas.93.8.3188. View

17.

Cooper C, Khan Mirzaei M, Nilsson A . Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics. Front Microbiol. 2016; 7:1209. PMC: 4971087. DOI: 10.3389/fmicb.2016.01209. View

18.

Markoishvili K, Tsitlanadze G, Katsarava R, Morris Jr J, Sulakvelidze A . A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol. 2002; 41(7):453-8. DOI: 10.1046/j.1365-4362.2002.01451.x. View

19.

Rhoads D, Wolcott R, Kuskowski M, Wolcott B, Ward L, Sulakvelidze A . Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009; 18(6):237-8, 240-3. DOI: 10.12968/jowc.2009.18.6.42801. View

20.

Kvachadze L, Balarjishvili N, Meskhi T, Tevdoradze E, Skhirtladze N, Pataridze T . Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol. 2011; 4(5):643-50. PMC: 3819013. DOI: 10.1111/j.1751-7915.2011.00259.x. View